# EDGAR Filing Document

**Accession Number:** 0000316253
**File Stem:** 0000921895-25-001834
**Filing Date:** 2025-6
**Character Count:** 11241
**Document Hash:** 952b4172f909370d2760ac0aca29ebe9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-001834.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0000921895-25-001834

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENZO BIOCHEM INC
- **CENTRAL INDEX KEY:** 0000316253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 132866202
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-32878
- **FILM NUMBER:** 251074037

**BUSINESS ADDRESS:**
- **STREET 1:** 60 EXECUTIVE BLVD
- **CITY:** FARMINGDALE
- **STATE:** NY
- **ZIP:** 11735
- **BUSINESS PHONE:** 5167555500

**MAIL ADDRESS:**
- **STREET 1:** ENZO BIOCHEM INC
- **STREET 2:** 60 EXECUTIVE BLVD
- **CITY:** FARMINGDALE
- **STATE:** NY
- **ZIP:** 11735
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radoff Bradley Louis
- **CENTRAL INDEX KEY:** 0001380585

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 2727 KIRBY DRIVE
- **STREET 2:** UNIT 29L
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77098

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**ENZO BIOCHEM INC**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**294100102**

*(CUSIP Number)*

**BRADLEY L. RADOFF**<br>2727 Kirby Drive<br>Unit 29L<br>Houston TX 77098<br>713-482-2196

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **294100102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Radoff Family Foundation** | Name of reporting person<br>**Radoff Family Foundation** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**430000.00** | Aggregate amount beneficially owned by each reporting person<br>**430000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.8%** | Percent of class represented by amount in Row (11)<br>**0.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **294100102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Radoff Bradley Louis** | Name of reporting person<br>**Radoff Bradley Louis** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4390882.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**430000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4390882.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**430000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4820882.00** | Aggregate amount beneficially owned by each reporting person<br>**4820882.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.2%** | Percent of class represented by amount in Row (11)<br>**9.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
ENZO BIOCHEM INC

**(c) Address of Issuer's Principal Executive Offices:**
60 EXECUTIVE BLVD, FARMINGDALE, NY, 11735

**Item 4. Purpose of Transaction**

Item 4 is hereby amended to add the following:

On June 23, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bethpage Parent, Inc., a Delaware corporation ("Parent"), and Bethpage Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to and subject to the terms of the Merger Agreement, Merger Sub will merge with and into the Issuer, with the Issuer continuing as the surviving corporation of the merger (the "Merger") and a wholly owned subsidiary of Parent, as more fully described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 24, 2025.

Concurrently with the execution of the Merger Agreement, Mr. Radoff, solely in his capacity as a shareholder of the Issuer, and certain other parties entered into separate voting and support agreements (each, a "Voting and Support Agreement") in favor of Parent and Merger Sub. Under the terms of the Voting and Support Agreement, Mr. Radoff has agreed to vote all of his Shares in favor of the Merger and the adoption of the Merger Agreement and against any alternative transaction proposal. In addition, Mr. Radoff has agreed not to take certain actions, including (i) transferring any Shares (subject to certain exceptions), (ii) granting any proxies or powers of attorney or (iii) exercising any dissenters' rights with respect to the Merger. The Voting and Support Agreement terminates in certain circumstances, including, among others, upon the valid termination of the Merger Agreement in accordance with its terms (subject to certain limited exceptions) and by written agreement of Parent and each securityholder party thereto.

The foregoing description of the Voting and Support Agreement is not complete and is qualified in its entirety by reference to the full text of the form of Voting and Support Agreement, which is attached hereto as Exhibit 99.1.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) is hereby amended and restated to read as follows:

The aggregate percentage of Shares reported owned by each person named herein is based upon 52,432,129 Shares outstanding as of June 19, 2025, which is the total number of Shares outstanding as reported in the Merger Agreement attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 24, 2025.

As of the date hereof, the Radoff Foundation directly beneficially owned 430,000 Shares, constituting approximately 0.8% of the Shares outstanding.

As of the date hereof, Mr. Radoff directly beneficially owned 4,390,882 Shares, constituting approximately 8.4% of the Shares outstanding. Mr. Radoff, as a director of the Radoff Foundation, may be deemed the beneficial owner of the 430,000 Shares owned by the Radoff Foundation, which together with the 4,390,882 Shares he directly owns, constitutes an aggregate of 4,820,882 Shares beneficially owned by Mr. Radoff, constituting approximately 9.2% of the Shares outstanding.

The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each Reporting Person disclaims beneficial ownership of the Shares that he or it does not directly own.

**(b)**
Item 5(b) is hereby amended and restated to read as follows:

Each of the Radoff Foundation and Mr. Radoff may be deemed to share the power to vote and dispose of the Shares directly beneficially owned by the Radoff Foundation.

Mr. Radoff has the sole power to vote and dispose of the Shares directly beneficially owned by him.

**(c)**
Item 5(c) is hereby amended and restated to read as follows:

There have been no transactions in securities of the Issuer by the Reporting Persons during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended to add the following:

On June 23, 2025, Mr. Radoff, Parent and Merger Sub entered into the Voting and Support Agreement as defined and described in Item 4 above.

Mr. Radoff has been awarded 378,179 RSUs in his capacity as a director of the Issuer, 235,282 of which have vested as of the date hereof. Mr. Radoff's remaining 142,897 RSUs vest upon the earlier of (i) January 16, 2026 or (ii) a change of control event.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Radoff Family Foundation

**Signature:** /s/ Bradley L. Radoff

**Name/Title:** Bradley L. Radoff, Director

**Date:** 06/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Radoff Bradley Louis

**Signature:** /s/ Bradley L. Radoff

**Name/Title:** Bradley L. Radoff

**Date:** 06/25/2025